
UK-Norwegian collaboration to trial peptide for rare cancer
Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase II clinical trial for patients with adrenocortical carcinoma (ACC). CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets… Read More















